Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.
April 17, 2024 10:15 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most...
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate
March 27, 2024 02:30 ET
|
Vidac Pharma Holding PLC
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate London (UK), March 27, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G;...
Global Photodynamic Therapy Devices Market Report 2024: Analysis of Products, Applications, End-users and Regional Dynamics to 2034 Featuring Coherent Corp, Biolitec, & Lumibird Medical Among Other Key Players
March 11, 2024 14:11 ET
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Photodynamic Therapy Devices Market Analysis & Forecast to 2024-2034: Market By Product; By Application; By End-user; and By Region" report...
Vidac Pharma va mener une étude de phase 2b du VDA-1102, son candidat médicament pour le traitement de la kératose actinique en collaboration avec CentroDerm
December 19, 2023 01:00 ET
|
Vidac Pharma Holding PLC
Londres (Royaume-Uni), 19 décembre 2023 – Vidac Pharma Holding Plc (Hambourg et Stuttgart : T9G ; ISIN : GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, a...
Vidac Pharma to conduct Phase 2b study for actinic keratosis therapeutic candidate VDA-1102 with CentroDerm
December 19, 2023 01:00 ET
|
Vidac Pharma Holding PLC
London (UK), December 19, 2023 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company, has completed...
Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study
November 28, 2023 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver based biopharmaceutical company with a focus on skin disease, is excited to announce that...
Global Photodynamic Therapy Market Analysis & Forecast 2024-2034: Innovations in Photodynamic Therapy Devices Propel Growth, with Cancer Treatment and Skin Conditions at the Forefront
November 02, 2023 10:03 ET
|
Research and Markets
Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "Global Photodynamic Therapy Market Analysis & Forecast 2024-2034: Market By Product; By Applications; By End-user; and By Region" report has been...
Photodynamic Therapy Market to Grow at a CAGR of 13.5% from 2022 to 2031, reaching US$ 15.5 Billion: As per TMR Study
July 17, 2023 15:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, July 18, 2023 (GLOBE NEWSWIRE) -- The global photodynamic therapy market stood at US$ 4.2 billion in 2021, and the global market is projected to reach US$ 15.5...
Global Photodynamic Therapy Market to 2031 - Featuring Galderma, Bausch Health and Lumenis Among Others
January 04, 2023 04:18 ET
|
Research and Markets
Dublin, Jan. 04, 2023 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Global Market Opportunities And Strategies To 2031: COVID-19 Implications And Growth" report has been added to ...
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
November 21, 2022 08:48 ET
|
Biofrontera Inc.
WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...